To assess the feasibility of providing guideline-based cardiovascular disease (CVD) prevention care within the context of a community-based health insurance program (CBHI) in rural Nigeria.
INTRODUCTION
Cardiovascular disease (CVD) has become a leading contributor to the burden of disease in low-and middle-income countries (LMICs), including sub-Saharan Africa (SSA). 1 The World Health Organization (WHO) has developed guidelines for CVD prevention in LMICs.2 However, it is unclear whether it is feasible to implement these guidelines in settings with dysfunctional health systems.3 CVD prevention care is unaffordable for many patients in SSA.4 Quality of care is often insufficient with a lack of facilities, qualified staff, essential equipment and supplies, and limited organizational capacity to provide chronic care.3 Operational research of CVD prevention care programs in SSA is urgently needed to evaluate how guidelines can be successfully translated into practice. [5] [6] [7] The operational research project QUality Improvement Cardiovascular care Kwara (QUICK) aimed to assess the feasibility of CVD prevention care according to WHO2 and other international guidelines, [8] [9] [10] in the context of a community-based health insurance (CBHI) program in rural Nigeria. This insurance program ensured access to care for patients by covering the costs of care, and at the same time provided financial and technical support to improve the quality of care in the participating healthcare clinics.11 Here we report on the feasibility of CVD prevention care in this context, with quality of care as the main outcome. The financial feasibility of providing CVD prevention care is described elsewhere (chapter seven).
METHODS
The study protocol is described in detail elsewhere.12 A summary is described below.
Context

The Health Insurance Fund
The Health Insurance Fund (HIF) subsidizes CBHI programs for low-and middle-income groups in several African countries. The health maintenance organization Hygeia has contracted both private and public clinics to provide the care for the enrolees in HIF's program in Nigeria, called the Hygeia Community Health Care (HCHC) program (see Text, Supplemental Digital Content 1, which describes the HCHC program in more detail).
Study site and context
Ogo Oluwa Hospital (OOH) in Kwara State is a private primary healthcare clinic participating in the HCHC program. It provides care for the population of Bacita, a rural, low-income community. Guidelines for CVD prevention were unavailable in OOH before the start of the HCHC program. Facilities to screen for target organ damage (TOD) were absent and registration of patient treatments and outcomes was poor. As part of the quality improvement component of the HCHC program, CVD prevention guidelines were introduced in OOH in June 2010 and included provision of equipment for diagnostic testing, introduction of treatment protocols (see Supplemental Digital Content 2, which shows the treatment algorithms for hypertension and diabetes treatment), quarterly staff training with feedback on guideline adherence, 96 and organizational support, including introduction of standardized patient files and laboratory forms. CVD prevention care, upgrading, and support were financed through the insurance program. However, as TOD screening was considered unaffordable within the insurer's reimbursement fees by the medical director of OOH, consumables required for TOD were provided in the context of the QUICK study.
Study design and study participants
The QUICK study was an observational prospective hospital-based cohort study of 349 adults (see Text, Supplemental Digital Content 1, which provides more details on the sample size), recruited between June 2010, directly after guideline implementation, and January 2011.
Patients at increased risk of CVD (i.e. diagnosed with hypertension, diabetes, renal disease or established CVD), who were enrolled in the HCHC program and attending the clinic, were consecutively included if none of the following exclusion criteria were present: pregnancy/ lactating, suspected secondary hypertension, not residing in Kwara State. All patients were followed for one year and visited a study nurse every three months, in addition to the regular monthly doctors' appointments (see Text, Supplemental Digital Content 1, which provides more details on data collection).
Outcome measures and data collection
The primary outcome was quality of care measured using the adjusted cardiovascular care quality indicators of the United Kingdom National Health Services Quality and Outcome Framework (QOF),12,13 1.5 year after the implementation of CVD prevention guidelines. The indicators included process and patient outcome indicators. Scoring of quality of care was done by three independent medical doctors (i.e. not part of OOH staff, not involved in data analysis) in a cross-sectional audit of the medical records of all patients included in the QUICK cohort.
Secondary outcomes included 1) the proportion of patients who obtained risk factor control at 12 months of follow up, 2) operational and behavioural determinants of treatment success in hypertensive patients and 3) health system-related barriers to CVD prevention guideline implementation.
Blood pressure was measured at each study visit. Three measurements were performed with the patient in sitting position, after five minutes of rest, using a validated automatic blood pressure device with a cuff suitable for different arm circumferences (ranging from 22 cm to 42 cm) (OMRON M6 Comfort, OMRON Cooperation). The mean of the 2nd and 3rd measurement was used for analysis. Health system-related barriers to guideline implementation were identified during training sessions with the hospital staff using interviews. Perceived barriers were systematically recorded using standardized record forms. In addition, hospital records were collected to monitor stocks and staff-turnover.
Data monitoring procedures were implemented to assure the quality of study data (see Text, Supplemental Digital Content 1, which provides more details on data monitoring).
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Data analysis
Quality indicator scoring
For each indicator, the denominator to calculate percentage passed was the total number of patients for which a quality indicator was applicable. The nominator was the number of patients for whom the indicator was achieved.13 Each indicator allowed for exception reporting as recommended by the QOF Framework,13 for example if there was a contraindication for a specific test or treatment, in which case the record did not count in the denominator. Therefore, the denominator for a specific indicator, for example for hypertension control, and the number of patients with hypertension included in the cohort varied.
Secondary outcomes
The proportion of patients who achieved risk factor control after one year of follow up was determined using descriptive statistics. Determinants of treatment success in hypertension patients, defined as blood pressure below 140 mmHg systolic and 90 mmHg diastolic, were evaluated using multivariable logistic regression. All follow up visits (at 3, 6, 9 and 12 months) were included. Mixed models, corrected for clustering at patient level, accounted for repeated observations on the same patient. The following operational and behavioural predictors for treatment success were explored: missing doctor's appointments, travel time to and waiting time in the clinic, travel mode, travel costs, income or productivity losses due to clinic visits, out-ofpocket expenditures for healthcare, drug stock-outs, adherence to drugs and lifestyle advices, drug side effects, use of traditional medicine, consultation of other healthcare providers, and doctor's prescription of maximum indicated drug doses. Plausible confounders explored in all analyses were biological (age, gender, baseline blood pressure, co-morbidities, BMI) and socioeconomic patient characteristics (ethnicity, marital status, education, wealth, job type) that may have altered the probability of successful treatment. To account for initial drug titration in patients not on treatment upon inclusion, other confounders tested were being on treatment upon inclusion, duration of study follow-up and drug intensity (number and dose of anti-hypertensive agents). Plausible interactions were explored. The decision to include a variable in the final model was based on a significant change (greater or equal to 5%) in the overall fit of the model. Predictors for the main determinants of treatment success were also explored using the same methodology. Data were analyzed using STATA, version 12.1 (StataCorp LP, Texas, USA).
Health system barriers to guideline implementation were reported according to the framework for chronic disease care as reported by Maimaris et al.6
Definitions
The QOF quality indicators used blood pressure targets that differed from international guidelines of CVD prevention care2,8,9 because the audit standard is less stringent than targets recommended in treatment guidelines. 2, 8, 9, 13 We used the QOF definition of blood pressure control for the primary outcome for comparability with other studies that reported quality of care according to QOF indicators. This is defined as a blood pressure of ≤ 150 mmHg systolic and ≤ 90 mmHg diastolic for hypertensive patients without diabetes and ≤ 145 mmHg systolic and ≤ 85 mmHg diastolic for hypertensive patients with diabetes. For all secondary outcomes, 98 blood pressure control was defined as < 140 mmHg systolic and < 90 mmHg diastolic, irrespective of co-morbidities, similar to other studies from SSA.14-17
The remaining definitions can be found in the Supplemental Digital Content (see Text, Supplemental Digital Content 1, which describes all outcome definitions).
Ethical Review
Ethical clearance was obtained from the Ethical Review Committee of the University of Ilorin Teaching Hospital in Nigeria. Informed consent was obtained from all study participants by written signature or fingerprint.
RESULTS
Patient characteristics
The QUICK cohort consisted of 349 patients. Participants flow is shown in Figure 1 . Ninety-five percent (n = 331) of the patients were included based on a diagnosis of hypertension. Other reasons for inclusion are shown in *229 patients were in active follow up and receiving CVD preventive drug treatment upon inclusion, 120 patients had not been on CVD preventive treatment for at least 1 year upon inclusion. IQR= inter quartile range, HT = hypertension, DM = diabetes mellitus, BP= blood pressure, LDL =low-density lipoprotein, HDL = high-density lipoprotein, LVH= left ventricular hypertrophy. *N=331; patients already on treatment at inclusion: N=213; patients not on treatment at inclusion: N=118. **Any target organ damage includes the presence of LVH, renal impairment, pathological Q waves on ECG, stroke and/or angina pectoris as diagnosed by a doctor and angina pectoris based on screening of the Rose questionnaire. ^n=348.
Retention in care, mortality and CVD events
One year follow up was completed for 323 patients (92.5%). Eleven patients died during the study period (3.2%). Causes of death and reasons for study drop out are shown in Figure 1 . Out of the 349 patients included in the QUICK cohort, four patients were diagnosed with stroke, one with angina pectoris, and three patients had newly developed pathological Q waves on ECG, during the follow up period.
Quality of care
Quality of care scoring was performed for the following QOF disease categories: primary prevention, hypertension, diabetes, smoking and obesity. Heart failure, stroke, and chronic kidney disease were excluded as the limited number of patients in the cohort with these conditions did not allow reliable scoring of the indicators. Amongst 349 patients, three medical files could not be retrieved. All three patients had died during the follow up. The results of the scoring on all indicators are described in Table 2 .
Process indicators
A record of CVD risk factor and TOD screening during the follow-up period was found in 114 of 115 (99.1%) files of eligible patients with newly diagnosed hypertension. A record of lifestyle advice was found in 249 of 333 (74.8%) files of patients eligible for lifestyle advice. A recent record of blood pressure measurement was found in 292 of 328 (89%) files of eligible patients with hypertension (Table 2) . Table 2 Quality scoring 1.5 year after the implementation of CVD prevention guidelines in the study clinic Description N* Passed (%)
PRIMARY PREVENTION
Percentage of patients with a new diagnosis of hypertension (excluding those with pre-existing coronary heart disease, diabetes, stroke and/or transient ischemic attack) who have a record of a face to face cardiovascular risk assessment using an agreed risk assessment tool including blood tests. 
HYPERTENSION
Process indicators
The practice can produce a register of patients with established hypertension. Yes
Description N* Passed (%)
Percentage of patients with hypertension who have a record of the blood pressure in the previous 9 months. 328 292 (89.0)
Outcome indicators
Percentage of patients with hypertension in whom the last blood pressure (measured in the previous 9 months) is 150/90 or less. 328 211 (64.3)
DIABETES
Process indicators
The practice can produce a register of all patients aged 17 years and over with diabetes mellitus. 
Outcome indicators
Percentage of patients with diabetes in whom the last blood pressure is 145/85 or less. 53 29 (54.7)
Percentage of patients with diabetes in whom the last fasting blood glucose is 7 mmol/l or less, or random blood glucose 14 mmol/l or less.
Percentage of patients with diabetes whose last measured total cholesterol is 5mmol/l or less. 53 37 (69.8)
SMOKING
Process indicators
Percentage of patients who have a record of smoking status. 349 247 (70.8)
Percentage of patients who smoke who have a record that smoking cessation risk advice has been offered. 5 2 (40.0)
OBESITY
Process indicators
The practice can produce a register of patients aged 18 and over with a BMI greater than or equal to 30 in the previous 12 months.
No *N= number of records for which indicator was applicable (denominator to calculate percentage passed). Due to exception reporting the denominator varies per indicator. Patient files that could not be retrieved are included in the denominator where appropriate (for example, a patient with hypertension for whom the patient file was not found was included in the denominator of the hypertension indicators) and are considered not to have passed the indicator.
A recent record of blood glucose measurement was found in 51 of 53 (96.2%) files of patients with diabetes, 52 (98.1%) files had a record of blood pressure measurement. Screening for microalbuminuria, impaired estimated Glomerular Filtration Rate and high cholesterol was recorded in 98.1% of diabetes cases. Physical examination to screen for retinal damage, peripheral artery disease and neuropathy was recorded in 43.4%, 18.9% and 17% of the files respectively (Table 2) .
Outcome indicators
Of the 328 hypertensive patients who were eligible for the blood pressure outcome indicator, 211 (64.3%) cases had a blood pressure that was measured in the last nine months and that 102 was on target (≤ 150 mmHg systolic and ≤ 90 mmHg diastolic)( Table 1 , Supplemental Digital Content 3, which describes risk factor control at baseline and 12 months for each risk factor).
Predictors for hypertension treatment success
Predictors for hypertension treatment success were evaluated using multivariable regression analyses. Patients who had missed an appointment with their doctor in the last three months were less likely to have controlled blood pressure (< 140 mmHg systolic and < 90 mmHg diastolic) compared to patients who did not miss appointments (OR 0.58, 95%CI 0.36-0.95 for 1 missed appointment ranging to OR 0.35, 0.17-0.70 for >2 missed appointments; Table 3 ).
Patients with a medium or high adherence to drug treatment according to the Morisky adherence scale18 were more likely to have controlled blood pressure (medium adherence OR 1.91, 95%CI 1.09-3.36; high adherence OR 2.68, 1.59-4.53, Table 3 ) compared to patients with low adherence. Other variables that were significantly associated with successful treatment were shorter waiting time in the clinic during doctor's appointments, and a healthy lifestyle (Table   3 ). Only 6 of the 331 (1.8%) hypertension patients were prescribed the maximum recommended dose of three anti-hypertensive drugs and none of them continued the maximum dose during follow up.
Factors significantly associated with missing appointments included low adherence to drugs, long waiting time in the clinic, high travel costs, loss of income due to doctor's appointments and travelling to the clinic with private travel means. Patients who reported missing appointments with the doctor, or who reported drug stock-outs or drug side effects, were less likely to be highly adherent to drugs (see Table 2 , Supplemental Digital Content 3, which provides predictors for missing appointments and for high adherence using multivariable regression analyses). Table 4 lists the main barriers to effective guideline implementation encountered during QUICK follow up. Challenges were observed in the following health system domains: human, physical and intellectual resources, health system financing, and health system governance and delivery. Limited knowledge translation between doctors on guideline-based care.
Health system barriers to guideline implementation
Physical resources
Combination drug formulas or higher dose formulations CVD prevention drugs not available Over 90% of hypertension patients in QUICK cohort received multidrug therapy leading to large numbers of pills prescribed per day.
Risk of poor adherence to drugs.
Facilities for diabetes care insufficient HbA1c tests not available, home-based insulin treatment not available (no facilities for home monitoring of glucose, insulin not affordable)
Only oral anti-diabetic treatment available.
Drug stock-outs Several drug stock-outs. Patients needed to buy drugs outside clinic and pay out-of-pocket.
Intellectual resources
Limited knowledge and skills doctors CVD risk stratification including TOD screening perceived as too complicated (e.g. ECG interpretation).
TOD screening not feasible in primary care settings. Risk of poor adherence to drugs.
Lack of efficient organization of outpatient clinics Long waiting times in clinics (median 5 hours, IQR 2 hours).
Risk of poor patient compliance to doctor's appointments, leading to increased risk of treatment failure.
Lack of external quality control organizations to monitor quality of laboratory Implementation of external quality control for laboratory was not possible due to limited number of accredited quality control organizations and high costs.
External quality control laboratory not feasible.
CVD= cardiovascular disease, OOH = Ogo Oluwa Hospital, IQR inter quartile range, TOD = target organ damage
DISCUSSION
Our study demonstrated that high quality CVD prevention care according to international guidelines2,8-10 can be provided within the context of a CBHI program, in a rural primary care setting in SSA. We observed a very high patient retention in care of over 90% and high scores on process and outcome quality indicators. Several factors are likely to have contributed to these results. First, the availability of insurance has most likely contributed to the high patient retention by removing the barrier of costs of care for patients. A pilot study in a health facility nearby the study clinic with a similar patient population but without access to insurance showed that many patients did not return after initial diagnosis. Most other prospective studies from SSA describing CVD prevention care programs, also report high loss to follow up rates, the majority over 50% at one year of follow up.19-24 Studies reporting higher patient retention provided free care.14,25 Second, the insurance program provided resources for quality improvement. Other elements that have likely contributed to the high quality of care include implementation of treatment algorithms based international guidelines, training and feedback sessions, and standardization of patient files and laboratory forms.
Our study also identified several health system barriers to CVD prevention care despite the availability of health insurance. The high workload and high turnover of doctors constrained knowledge translation between healthcare professionals. TOD screening as recommended by WHO guidelines2 was considered too complicated, too time consuming, and too expensive for use in routine clinic settings within the reimbursement system of the insurer. Similar financial constraints were reported for high dose multidrug regimes and insulin and HbA1c
tests. The unaffordability of multidrug regimes may explain why almost none of the patients with uncontrolled blood pressure were prescribed the recommended maximum dose drug regime, although patient-related factors, such as poor drug adherence, may also have discouraged doctors from prescribing more drugs. The unavailability of insulin may have resulted in the relatively low blood glucose control in diabetes patients. Long waiting times in the clinic, travel costs to the clinic and income loss due to frequent clinic visits were shown to compromise patient adherence to monthly doctor's appointments, thereby increasing the risk of treatment failure. However, monthly doctor's appointments were considered necessary for patient retention in care and because alternative drug supply systems were not available. Similar barriers have also been reported by other studies from SSA.4,23,25
We included patients attending a single private primary healthcare clinic in our study.
Inclusion of patients attending public facilities and secondary and tertiary care facilities would have allowed us to measure setting-specific variations. However, 69% of total health expenditure in Nigeria are private expenditures26 and private facilities account for a high percentage of health expenditures.27 In addition, CVD prevention care should preferably be provided at a primary care level.5 Therefore, our study clinic represents a typical primary healthcare setting in SSA and many of our health system related findings can be generalized to other settings in SSA.
The facilitation of TOD screening may have led to a bias towards better blood pressure control rates, since guidelines recommend a multidrug regime for patients with grade 1 hypertension and TOD. However, only 15 patients with grade 1 hypertension combined with TOD were receiving monotherapy at baseline, other patients were already on multidrug regimes. In only 10 of these patients treatment was intensified. Therefore, we believe the TOD screening facilitation did not affect the blood pressure control rates observed in our study.
Studies from high income countries describing quality of CVD prevention care in primary care practices using the QOF indicators, reported similar scores on the outcome indicators as observed in our study. Achievement of process indicators ranged between 70% to over 90%28-36 outcomes or systematically collected data on health system related barriers to guideline implementation. The inclusion of quality indicators and health system barriers to care as outcome measures in our study allowed analysis of the problems that limit effective CVD prevention care implementation. Other strengths of our study include the prospectively collected data, the intensive monitoring of data quality and the low loss to study follow up. Therefore, our study provides high quality data from an understudied region in the world that can be used for the design of urgently needed CVD prevention programs in SSA.
Our study demonstrated that implementation of CVD prevention care was feasible within a CBHI program. However, provision of high quality care was resource intense and involved considerable costs (chapter seven). Rapid scale-up of CVD prevention care in SSA according to current WHO CVD prevention guidelines2 may be too demanding, especially in settings where CBHI programs are not available. Therefore, more efficient models of care delivery should be explored. Simplified treatment protocols could facilitate task-shifting to nurses and community-health workers and facilitate alternative drug supply systems such as mobile pharmacies. A fixed-dose combination pill (the so-called "polypill") containing cheap generic anti-hypertensive drugs and a statin for all patients at risk of CVD may be a promising opportunity for primary care settings in SSA due to its simplicity, promise of better patient adherence and potential for cost reduction.50,51
Expensive TOD screening and complicated drug regimes with step-wise drug titration would no longer be needed for the majority of patients as all patients at risk of CVD would receive multidrug therapy irrespective of individual risk profiles. Simple treatment protocols with combination pills and partial task-shifting to medical assistants were also key elements of a recent, very successful, quality improvement program for hypertension within an insurance program from the United States that resulted in blood pressure control rates of over 80%52 However, more research is needed to establish effectiveness and safety of these new interventions.
CONCLUSION
Our study demonstrated that high quality CVD prevention care can be successfully imple- 
Coverage within the HCHC program in Kwara
The There is no limit to the number of visits to the health facilities for patients but as a large share of the payment from the insurer to the healthcare provider is paid through capitation fees, healthcare providers are encouraged to prevent overutilization of services.
Methods
Sample size
The number of patients needed for reliable scoring of quality indicators differs per indicator and ranges from less than 50 patients to over 100 patients to achieve 90% confidence intervals of +/-10 points on estimated pass rates.9 Therefore, the target sample size of 300 patients was based on the secondary outcome of number of patients in whom CVD risk factors were treated successfully.10 Assuming 30% of patients would be treated successfully, 300 patients would provide sufficiently narrow confidence limits around the estimate (95% CI: 24.9% -35.5%).The aim was to include 150 patients who were attending the clinic for CVD preventive drug treatment prior to the start of the study, and 150 patients who had not received any CVD preventive drug treatment for at least one year upon inclusion. Evaluation of the feasibility to reach the distribution across the two subgroups took place three months after the start of inclusion, according to protocol. Because the majority of included patients were already receiving treatment upon inclusion, the sample size was increased to 350 and the last 50 patients included were limited to patients who were not yet receiving treatment.
Definitions
Glucose at target level was defined as fasting plasma glucose < 7.0 mmol/l or random plasma glucose of <12 mmol/l.
Lipid control was defined according to World Health Organization recommendations.11 Target levels for primary prevention were total cholesterol < 5.0 mmol/L and LDL cholesterol < 3.0 mmol/l. Targets for secondary prevention were total cholesterol < 4.0 mmol/L and LDL cholesterol < 2.5 mmol/l.
Presence of renal impairment was defined as an estimated Glomerular Filtration Rate < 60 mL/ min/1.73m2.12
Target organ damage was defined as ECG-based LVH according to Sokolov Lyon criteria, renal impairment, pathological Q waves on ECG, stroke or angina pectoris.10 Microalbuminuria was excluded from this definition as a community-based study in an area nearby demonstrated microalbuminuria was also prevalent in non-hypertensive subjects, indicating it was is not a good marker for hypertensive target organ damage in this population.13 Proteinuria was excluded as it was not feasible to get accurate results based on a quantitative dipstick analysis.
Hypertension was classified according to JNC7 guidelines,14 adherence was scored using the Morisky scale.15
Data collection
Patients were seen by a study nurse every three months, in addition to their regular doctor's appointments. Patients were reminded of their study visits by telephone and text messages or during market days in the community. If patients could not be reached and did not show for study visits, a home visit by the study nurse was undertaken to assess the reason for no show. For regular doctor's appointments, no reminders were sent and no home visits were undertaken.
Data monitoring
All Case Record Forms at the study site were checked weekly by a clinical research associate (CRA) for inconsistencies before double data entry. Entered data were also monitored for inconsistencies and data query reports were resolved at the study site on a three monthly basis using source documents. Three monthly monitoring visits to the study site and data entry unit were conducted by a CRA to monitor adherence to the study protocol and procedures by study staff.
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